Zobrazeno 1 - 10
of 46
pro vyhledávání: '"David B. Bregman"'
Publikováno v:
Anemia, Vol 2013 (2013)
Several intravenous iron complexes are available for the treatment of iron deficiency anemia (IDA). Iron dextran (DEX) is associated with an elevated risk of potentially serious anaphylactic reactions, whereas others must be administered in several s
Externí odkaz:
https://doaj.org/article/3036d86128514b1cbea6f7823496a425
Publikováno v:
Anemia, Vol 2012 (2012)
Background. Iron deficiency anemia (IDA) is a common hematological complication with potentially serious clinical consequences that may require intravenous iron therapy. Ferric carboxymaltose (FCM) is a stable, nondextran iron formulation administere
Externí odkaz:
https://doaj.org/article/85e784a8b44e49dd8c09491826ec2d1c
Autor:
P. C. Chang, Jorge Luiz Gross, Bruce W. Bode, Daniel L. Lorber, Janet B. McGill, David B. Bregman
Publikováno v:
Diabetes Care. 38:2266-2273
OBJECTIVE To compare the efficacy and safety of Technosphere insulin (TI) and insulin aspart in patients with type 1 diabetes. RESEARCH DESIGN AND METHODS This open-label noninferiority trial compared the change in HbA1c from baseline to week 24 of p
Publikováno v:
Journal of Bone and Mineral Research. 28:1793-1803
Fibroblast growth factor 23 (FGF23) is an osteocyte-derived hormone that regulates phosphate and vitamin D homeostasis. Through unknown mechanisms, certain intravenous iron preparations induce acute, reversible increases in circulating FGF23 levels t
Publikováno v:
Obesity Surgery. 23:1413-1420
Iron deficiency anemia (IDA) is a common finding in patients after bariatric surgery. The cause is multifactorial including reduced oral iron intake and malabsorption. While many patients can be managed with oral supplements, parenteral iron may be n
Publikováno v:
Anemia, Vol 2013 (2013)
Anemia
Anemia
Several intravenous iron complexes are available for the treatment of iron deficiency anemia (IDA). Iron dextran (DEX) is associated with an elevated risk of potentially serious anaphylactic reactions, whereas others must be administered in several s
Autor:
David B. Bregman, Chaim Charytan, Todd A. Koch, Angelia Butcher, David Morris, Marializa V. Bernardo
Publikováno v:
Nephrology Dialysis Transplantation. 28:953-964
Background Currently available intravenous (IV) iron agents vary in indication, dosing regimens and safety profiles. Ferric carboxymaltose (FCM) is a stable, non-dextran-containing iron formulation developed for rapid IV administration in high doses
Autor:
David B. Bregman, Robert G. Russell, Mark D'Amico, Chris Albanese, Mahadev Rao, Richard G. Pestell, Hanzhou Lian, Michael A. White, Kongming Wu, Maofu Fu
Publikováno v:
Cancer Research. 64:4122-4130
The Ink4a/Arf locus encodes two structurally unrelated tumor suppressor proteins, p16INK4a and p14ARF (murine p19ARF). Invariant inactivation of either the p16INK4a-cyclin D/CDK-pRb pathway and/or p53-p14ARF pathway occurs in most human tumors. Cycli
Publikováno v:
Biochemical and Biophysical Research Communications. 296:954-961
UV radiation induces DNA lesions that are repaired by the nucleotide excision repair (NER) pathway. Cells that are NER deficient such as those derived from xeroderma pigmentosum (XP) patients are susceptible to apoptosis after 10 J/m2 UV radiation, a
Erythropoiesis may be limited by absolute or functional iron deficiency or when chronic inflammatory conditions lead to iron sequestration. Intravenous iron may be indicated when oral iron cannot address the deficiency. Ferric carboxymaltose (FCM) is
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::28628859bea5af115e959476e1c26206
https://europepmc.org/articles/PMC3949301/
https://europepmc.org/articles/PMC3949301/